PMC:7195088 / 12361-12747 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"180","span":{"begin":148,"end":156},"obj":"Species"},{"id":"181","span":{"begin":377,"end":385},"obj":"Species"},{"id":"208","span":{"begin":84,"end":102},"obj":"Chemical"},{"id":"209","span":{"begin":319,"end":337},"obj":"Chemical"},{"id":"254","span":{"begin":139,"end":147},"obj":"Disease"},{"id":"255","span":{"begin":307,"end":315},"obj":"Disease"}],"attributes":[{"id":"A180","pred":"tao:has_database_id","subj":"180","obj":"Tax:9606"},{"id":"A181","pred":"tao:has_database_id","subj":"181","obj":"Tax:9606"},{"id":"A208","pred":"tao:has_database_id","subj":"208","obj":"MESH:D006886"},{"id":"A209","pred":"tao:has_database_id","subj":"209","obj":"MESH:D006886"},{"id":"A254","pred":"tao:has_database_id","subj":"254","obj":"MESH:C000657245"},{"id":"A255","pred":"tao:has_database_id","subj":"255","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although based on low-level evidence and pending RCT results, in our opinion, early hydroxychloroquine administration may be considered in COVID-19 patients manifesting moderate to severe symptoms, whereas further data are needed to better delineate the true balance between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and asymptomatic patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T63","span":{"begin":139,"end":147},"obj":"Disease"}],"attributes":[{"id":"A63","pred":"mondo_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Although based on low-level evidence and pending RCT results, in our opinion, early hydroxychloroquine administration may be considered in COVID-19 patients manifesting moderate to severe symptoms, whereas further data are needed to better delineate the true balance between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and asymptomatic patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T53","span":{"begin":84,"end":102},"obj":"Chemical"},{"id":"T54","span":{"begin":319,"end":337},"obj":"Chemical"}],"attributes":[{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"Although based on low-level evidence and pending RCT results, in our opinion, early hydroxychloroquine administration may be considered in COVID-19 patients manifesting moderate to severe symptoms, whereas further data are needed to better delineate the true balance between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and asymptomatic patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T79","span":{"begin":0,"end":386},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although based on low-level evidence and pending RCT results, in our opinion, early hydroxychloroquine administration may be considered in COVID-19 patients manifesting moderate to severe symptoms, whereas further data are needed to better delineate the true balance between possible favourable effects and toxicity of hydroxychloroquine in mildly symptomatic and asymptomatic patients."}